AML patient sample information used in this study
| Number . | Age . | Sex . | WHO diagnosis . | Cytogenetics . | % Blasts . |
|---|---|---|---|---|---|
| AML#1 | 69 | M | AML NOS | N/A | 60 |
| AML#2 | 66 | F | AML without maturation | Trisomy 9 | 90 |
| AML#3 | 41 | F | AML with t(6;9)(p23;q34); DEK-NUP214 | t(6;9) | 95 |
| AML#4 | 62 | M | AML with maturation | Complex | 55 |
| AML#5 | 70 | M | AML with maturation | Normal | 80 |
| AML#6 | 70 | M | AML without maturation | Complex | 95 |
| AML#7 | 91 | F | AML NOS | N/A | 60 |
| AML#8 | 55 | F | AML | Not available | 70 |
| AML#9 | 59 | F | AML with t(8;21)(q22;q22) RUNX1-RUNX1T1 | t(8;21) | 80 |
| AML#10 | 78 | F | AML without maturation | Normal | 95 |
| AML#11 | 58 | F | AML with maturation | Normal | 80 |
| AML#12 | 65 | M | AML with maturation | Trisomy 13 | 30 |
| AML#13 | 73 | F | AML without maturation | Normal | 95 |
| AML#14 | 49 | M | AML with myelodysplasia-related changes | N/A | 55 |
| AML#15 | 64 | F | AML with myelodysplasia-related changes | Normal | 45 |
| AML#16 | 65 | M | AML with minimal differentiation | Normal | 95 |
| AML#17 | 23 | F | AML without maturation | t(5;12) | 95 |
| AML#18 | 37 | M | AML without maturation | Normal | 90 |
| AML#19 | 59 | M | AML with t(8;21)(q22;q22) RUNX1-RUNX1T1 | t(8;21) | 60 |
| AML#20 | 65 | M | AML with maturation | Not available | 70 |
| AML#21 | 68 | M | Therapy-related AML | Not available | 40 |
| AML#22 | 63 | M | AML with myelodysplasia related changes | Not available | 30 |
| AML#23 | 76 | M | AML without maturation | Not available | 95 |
| AML#24 | 75 | M | AML with maturation | Complex | 55 |
| AML#25 | 88 | M | AML with maturation | Trisomy 8 | 30 |
| AML#26 | 35 | M | AML without maturation | 46 XY | 80 |
| AML#27 | 72 | M | AML with myelodysplasia-related changes | 46,XY isochrome (17)(q10) | 90 |
| Number . | Age . | Sex . | WHO diagnosis . | Cytogenetics . | % Blasts . |
|---|---|---|---|---|---|
| AML#1 | 69 | M | AML NOS | N/A | 60 |
| AML#2 | 66 | F | AML without maturation | Trisomy 9 | 90 |
| AML#3 | 41 | F | AML with t(6;9)(p23;q34); DEK-NUP214 | t(6;9) | 95 |
| AML#4 | 62 | M | AML with maturation | Complex | 55 |
| AML#5 | 70 | M | AML with maturation | Normal | 80 |
| AML#6 | 70 | M | AML without maturation | Complex | 95 |
| AML#7 | 91 | F | AML NOS | N/A | 60 |
| AML#8 | 55 | F | AML | Not available | 70 |
| AML#9 | 59 | F | AML with t(8;21)(q22;q22) RUNX1-RUNX1T1 | t(8;21) | 80 |
| AML#10 | 78 | F | AML without maturation | Normal | 95 |
| AML#11 | 58 | F | AML with maturation | Normal | 80 |
| AML#12 | 65 | M | AML with maturation | Trisomy 13 | 30 |
| AML#13 | 73 | F | AML without maturation | Normal | 95 |
| AML#14 | 49 | M | AML with myelodysplasia-related changes | N/A | 55 |
| AML#15 | 64 | F | AML with myelodysplasia-related changes | Normal | 45 |
| AML#16 | 65 | M | AML with minimal differentiation | Normal | 95 |
| AML#17 | 23 | F | AML without maturation | t(5;12) | 95 |
| AML#18 | 37 | M | AML without maturation | Normal | 90 |
| AML#19 | 59 | M | AML with t(8;21)(q22;q22) RUNX1-RUNX1T1 | t(8;21) | 60 |
| AML#20 | 65 | M | AML with maturation | Not available | 70 |
| AML#21 | 68 | M | Therapy-related AML | Not available | 40 |
| AML#22 | 63 | M | AML with myelodysplasia related changes | Not available | 30 |
| AML#23 | 76 | M | AML without maturation | Not available | 95 |
| AML#24 | 75 | M | AML with maturation | Complex | 55 |
| AML#25 | 88 | M | AML with maturation | Trisomy 8 | 30 |
| AML#26 | 35 | M | AML without maturation | 46 XY | 80 |
| AML#27 | 72 | M | AML with myelodysplasia-related changes | 46,XY isochrome (17)(q10) | 90 |
This table defines the nature of the AML disease, including WHO diagnosis and cytogenetics.
F, female; M, male; N/A, not applicable; NOS, not otherwise specified; WHO, World Health Organization.